Mariner, LLC Alkermes Plc. Transaction History

Mariner, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $264,571 - $324,686	-11,321 Reduced 60.56%	7,374 $204,000
Q3 2023 Nov 13, 2023	SELL	$27.17 - $31.97 $227,793 - $268,036	-8,384 Reduced 30.96%	18,695 $523,000
Q2 2023 Aug 11, 2023	BUY	$28.34 - $33.63 $52,287 - $62,047	1,845 Added 7.31%	27,079 $847,000
Q1 2023 May 12, 2023	BUY	$25.31 - $29.02 $314,122 - $360,167	12,411 Added 96.79%	25,234 $711,000
Q4 2022 Feb 14, 2023	BUY	$21.94 - $26.24 $281,336 - $336,475	12,823 New	12,823 $335,000

357

180M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.18B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

Stay updated on Mariner, LLC with notifications on news.